CSL Behring begins enrollment in Phase II/III trial of rVIIa-FP to treat hemophilia A or B
Around 54 male patients will be enrolled in the trial, which is designed to evaluate the pharmacokinetics (PK), efficacy, and safety of rVIIa-FP in these patients who have
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.